This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

PREMIUM, Observational Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2012 by Dr.Laurent Mineur, Institut Sainte Catherine.
Recruitment status was:  Active, not recruiting
Merck Serono International SA
BESPIM, CHU Nîmes (data analysis)
Information provided by (Responsible Party):
Dr.Laurent Mineur, Institut Sainte Catherine Identifier:
First received: December 20, 2012
Last updated: NA
Last verified: December 2012
History: No changes posted
PREMIUM is an observational pharmaco-epidemiologic, transversal, multi-centric, prospective cohort study and with independent investigators. The purpose is to compare PFS in real life with PFS clinical trials and to determine factors impacting efficacy and compliance to cetuximab treatment in first line K-ras wild-type (wt) metastatic colorectal cancer.

First Line WT KRAS mCRC

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Factors Impacting on Efficacy and Compliance to Cetuximab Treatment in First Line WT KRAS Metastatic Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by Dr.Laurent Mineur, Institut Sainte Catherine:

Primary Outcome Measures:
  • To compare PFS rate at 1 year with PFS in clinical studies (ITT and subgroup analysis) [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • ORR at 1 year (ITT and subgroup analysis) [ Time Frame: 3 years ]

Enrollment: 500
Study Start Date: January 2010
Estimated Study Completion Date: June 2013
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
First line WT KRAS mCRC

Detailed Description:
Retrospective studies have shown the influence of some factors on the efficacy of treatment with cetuximab (nicotine, magnesium etc..). No randomized study has compared the mode of administration of weekly and biweekly cetuximab. What are the factors influencing patient compliance? Adverse events, the relation between doctor and patient. PREMIUM will attempt to explore and assess the variables associated with efficacy and compliance to treatment and study practices in France for clinical management.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients from private and public centers

Inclusion Criteria:

  • patients > 18 years old diagnosed with mCRC
  • patients naïve for CT excepted for adjuvant setting or trated max 2 cycles CT in first line mCRC with or without cetuximab
  • all patients receiving cetuximab in first line treatment associated or not with CT
  • patients relapsed < 6 months after an adjuvant therapy

Exclusion Criteria:

  • patients participating to clinical trials
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01756625

Institut Sainte-Catherine
Avignon, Vaucluse, France, 84000
Sponsors and Collaborators
Dr.Laurent Mineur
Merck Serono International SA
BESPIM, CHU Nîmes (data analysis)
  More Information

Responsible Party: Dr.Laurent Mineur, Oncologist, Institut Sainte Catherine Identifier: NCT01756625     History of Changes
Other Study ID Numbers: PREMIUM
Study First Received: December 20, 2012
Last Updated: December 20, 2012

Keywords provided by Dr.Laurent Mineur, Institut Sainte Catherine:

Additional relevant MeSH terms:
Antineoplastic Agents processed this record on August 17, 2017